Platform Technology

Microcrystal Transdermal
Delivery Platform

A dissolvable microneedle architecture that carries pharmaceutical-grade microcrystals through the skin barrier — without needles, without GI involvement, without compromise.

< 200 µm
Microneedle height
±2%
Active loading tolerance
24 mo
Shelf life at 25 °C
ISO
Cleanroom manufacturing

Why it matters

A different class of delivery

Conventional oral supplementation is limited by absorption variability, GI tolerability, and patient adherence. The BioMed Labs platform addresses each of these constraints at the engineering level.

No GI Tract Involvement
Bypasses gastric acid, intestinal mucosa, and first-pass hepatic metabolism entirely.
No Injection Required
Self-administered. No sharps, no clinical setting, no trained personnel.
Defined Release Window
Release kinetics are engineered at the formulation stage, not governed by patient physiology.
Pharmaceutical-Grade Manufacturing
Produced under ISO-classified cleanroom conditions with full batch traceability.

Platform architecture

Six engineering pillars

Microcrystal Matrix Architecture

Each patch contains thousands of precisely engineered microcrystals loaded with active compound. The matrix geometry controls surface area exposure and governs the rate at which compound becomes available at the skin interface.

Dissolvable Microneedle Substrate

The microneedle substrate is fabricated from pharmaceutical-grade dissolvable polymers. On contact with skin moisture, the needle tips soften and release their payload into the upper dermal layers without penetrating the dermis.

Formulation Precision

Active compound loading is validated to ±2% per patch. Batch-to-batch consistency is maintained through closed-environment manufacturing and inline spectroscopic verification at each critical process step.

Controlled Release Kinetics

Release profile is determined by crystal habit, particle size distribution, and polymer dissolution rate — not by a membrane. This eliminates dose-dumping risk and allows the release curve to be tuned at the formulation stage.

Stability & Shelf Life

The anhydrous microcrystal matrix is inherently stable. Accelerated stability studies support a 24-month shelf life at 25 °C / 60% RH in the primary foil sachet, without refrigeration.

Platform Extensibility

The microcrystal platform is compound-agnostic. Formulation parameters are adjusted per active to accommodate solubility, molecular weight, and target release window — enabling rapid pipeline expansion.

Structural anatomy

Patch cross-section

Backing Layer — Flexible polymer filmMicrocrystal MatrixActive compound loaded · ±2% tolerance · Dissolvable polymer carrierStratum Corneum — Outermost skin barrierViable Epidermis — Compound uptake zoneUpper Dermis — Capillary network · systemic uptake① Backing② Matrix③ Microneedles④ Stratum corneum⑤ Epidermis⑥ Dermis
Flexible backing film
Dissolvable microneedle tips
Microcrystal payload
Stratum corneum
Viable epidermis
Upper dermis

See the platform in action

Follow the four-stage delivery sequence from patch application to systemic uptake.